iSpecimen Inc. Proceeds from Issuance or Sale of Equity
iSpecimen Inc. (ISPC) reported Proceeds from Issuance or Sale of Equity of $398.44 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-04-01
- iSpecimen Inc. proceeds from issuance or sale of equity for fiscal 2024 was $398.44K.
| Period end | Proceeds from Issuance or Sale of Equity | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|
| 2024-12-31 | $398.44K 10-K · filed 2025-04-14 | |
| 2024-10-29 | $5.00M 10-K · filed 2026-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |